Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

Article Figures & Data

Clinicopathological data of 256 patients in the anlotinib group

Characteristics	n = 256 (%)
Age (years)
≤ 60 years	137 (53.52)
> 60 years	119 (46.48)
Gender
Male	157 (61.33)
Female	99 (38.67)
Pathology
Adenocarcinoma	201 (78.52)
Squamous cell carcinoma or adenosquamous carcinoma	44 (17.19)
Other subtypes	11 (4.3)
Driver gene EGFR
Wild type (-)	172 (67.19)
Mutant type (+)	84 (32.81)
Driver gene ALK
Wild type (-)	248 (98.02)
Mutant type (+)	5 (1.98)
Unclear	3
Clinical staging
Stage III B	12 (4.69)
Stage IV	244 (95.31)
Metastasis
Number of metastases ≤ 3	155 (60.55)
Number of metastases > 3	101 (39.45)
History of tumor surgery
Yes	136 (53.13)
No	120 (46.88)
Number of previous chemotherapy regimens
2	146 (57.03)
> 2	110 (42.97)
Previous chemotherapeutic regimen
Pemetrexed + Platinum	182 (71.09)
Docetaxel + Platinum	165 (64.45)
Paclitaxel + Platinum	81 (31.64)
Vinorelbine + Platinum	67 (26.17)
Gemcitabine + Platinum	138 (53.91%)
History of radiotherapy
No	154 (60.16)
Yes	102 (39.84)
History of targeted medication
No	115 (44.92)
Yes	141 (55.08)
ECOG
0	54 (21.09)
1	202 (78.91)

Results of the prognostic factor analysis of patients from the anlotinib group (univariate analysis)

Item	PFS		OS
Item	P	HR (95%CI)	P	HR (95%CI)
Age	0.003	0.639 (0.478, 0.856)	0.456	1.126 (0.824, 1.538)
Post-treatment ECOG	0.445	1.164 (0.789, 1.717)	< 0.001	2.219 (1.489, 3.836)
Post-treatment granulocytes/lymphocytes	< 0.001	2.013 (1.405, 2.548)	< 0.001	2.651 (1.884, 3.732)
Pre-randomization maximal target lesion length	0.360	1.144 (0.857, 1.528)	< 0.001	2.049 (1.498, 2.803)
Hypertension	< 0.001	0.466 (0.341, 0.637)	0.004	0.617 (0.445, 0.854)
Hand-foot syndrome	< 0.001	0.476 (0.354, 0.640)	< 0.001	0.483 (0.348, 0.669)
Oral mucositis	0.031	0.693 (0.497, 0.967)	0.051	0.691 (0.476, 1.001)
Prolonged QT interval in ECG	0.010	0.646 (0.463, 0.900)	0.741	0.942 (0.662, 1.341)
Hyperglycemia	0.007	0.662 (0.491, 0.892)	0.735	1.059 (0.759, 1.477)
Hypertriglyceridemia	< 0.001	0.453 (0.329, 0.623)	< 0.001	0.462 (0.335, 0.639)
Hypercholesterolemia	0.001	0.558 (0.392, 0.794)	0.004	0.629 (0.540, 1.173)
Hyper-low density lipoproteinemia	0.001	0.502 (0.330, 0.762)	0.321	0.830 (0.516, 1.320)
Elevated thyroid stimulating hormone	0.001	0.591 (0.434, 0.805)	0.004	0.620 (0.449, 0.857)
Elevated alkaline phosphatase	0.008	1.519 (1.118, 2.065)	0.005	1.609 (1.159, 2.234)
Hypocalcemia	0.314	1.303 (0.778, 2.184)	0.012	1.876 (1.146, 3.071)
Hyponatremia	0.092	1.337 (0.954, 1.875)	0.001	1.971 (1.390, 2.795)
Hypomagnesemia	0.026	0.485 (0.256, 0.918)	0.468	0.789 (0.416, 1.497)

Results of the prognostic factor analysis of patients in the anlotinib group (multivariate analysis)

Item	PFS		OS
Item	P	HR (95%CI)	P	HR (95%CI)
Post-treatment ECOG score			0.002	2.073 (1.315, 3.269)
Post-treatment granulocytes/lymphocytes ratio	< 0.001	2.183 (1.523, 3.130)	< 0.001	2.423 (1.642, 3.576)
Pre-randomization maximal target lesion length			0.003	1.690 (1.190, 2.400)
Hypertension	0.040	0.688 (0.481, 0.983)
Hand-foot syndrome	0.002	0.582 (0.415, 0.815)
Hyperglycemia	0.007	0.632 (0.453, 0.884)
Hypertriglyceridemia	0.002	0.545 (0.569, 1.535)	0.002	0.520 (0.347, 0.778)
Elevated thyroid stimulating hormone	0.003	0.573 (0.399, 0.822)
Elevated alkaline phosphatase	0.044	1.425 (1.010, 2.011)

PFS and OS of each variable from the subgroups were divided on the basis of the cutoff values

	PFS		OS
	Median	P	Median	P
Post-treatment ECOG				0.0031
0-1 point			9.93
2-3 point			7.26
Post-treatment granulocytes/lymphocytes ratio		0.0008		< 0.0001
≤ 3.1	5.97		11.16
> 3.1	4.45		8.18
Pre-randomization maximal target lesion length (mm)				0.0002
≤ 72			10.38
> 72			7.98
Hypertension		< 0.0001
Yes	5.65
No	3.42
Hand-foot syndrome		< 0.0001
Yes	6.51
No	3.80
Hyperglycemia		0.0003
Yes	5.60
No	3.93
Hypertriglyceridemia		< 0.0001		< 0.0001
Yes	5.67		10.23
No	3.41		7.29
Elevated thyroid stimulating hormone		< 0.0001
Yes	5.66
No	3.61
Elevated alkaline phosphatase		0.0286
Yes	4.23
No	5.32